Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Medtronic
Harvard Business School
AstraZeneca
Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Navitoclax

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Navitoclax: Patents, clinical trial progress, indications

Navitoclax is an investigational drug.

There have been 15 clinical trials for Navitoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and Abbott.

There are one hundred and sixty-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Navitoclax
TitleSponsorPhase
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative NeoplasmAbbViePhase 1
A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With MyelofibrosisAbbViePhase 2
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic LeukemiaAbbViePhase 1

See all Navitoclax clinical trials

Clinical Trial Summary for Navitoclax

Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax

See all Navitoclax clinical trials

US Patents for Navitoclax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Navitoclax   Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Start Trial
Navitoclax   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
Navitoclax   Start Trial Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)   Start Trial
Navitoclax   Start Trial Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL)   Start Trial
Navitoclax   Start Trial Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Navitoclax

Drugname Country Document Number Estimated Expiration Related US Patent
Navitoclax Canada 2922341 2033-08-28   Start Trial
Navitoclax European Patent Office 3038618 2033-08-28   Start Trial
Navitoclax World Intellectual Property Organization (WIPO) 2015031608 2033-08-28   Start Trial
Navitoclax Argentina 102649 2034-11-14   Start Trial
Navitoclax Australia 2015347015 2034-11-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
McKesson
McKinsey
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.